Tech Company Financing Transactions
Fulcrum Therapeutics Funding Round
Fulcrum Therapeutics closed a $80 million Series B investment round on 9/6/2018. Investors included Foresite Capital, 6 Dimensions Capital and Casdin Capital.
Transaction Overview
Company Name
Announced On
9/6/2018
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Fulcrum's lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically-based neuromuscular, central nervous system and hematologic disorders.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
26 Landsdowne St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Fulcrum Therapeutics (Nasdaq: FULC) is here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. Above all we are champions for our patients. Trust, Respect, Compassion and Integrity define who we are.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Gould
Chief Scientific Officer
Owen Wallace
Vice President
Diego Cadavid
Vice President
Lucienne Ronco
VP - Finance
Peter Thomson
VP - Human Resources
Kim Hazen
Browse more venture capital transactions:
Prev: 9/6/2018: SpotHero venture capital transaction
Next: 9/6/2018: Yoco venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs